Dr. Reddy's Laboratories Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Dr. Reddy's Laboratories Limited generated cash of $45,433,000,000, which is less than the previous year. Cash used in financing activities reached the amount of -$3,763,000,000 last year. Net change in cash is therefore $1,328,000,000.
Cash Flow
| 2015 | 25.03B | -22.90B | -4.11B |
|---|---|---|---|
| 2016 | 41.24B | -20.42B | -17.00B |
| 2017 | 21.51B | -18.47B | -3.69B |
| 2018 | 18.02B | -14.88B | -4.44B |
| 2019 | 28.70B | -7.72B | -21.32B |
| 2020 | 29.84B | -4.92B | -25.15B |
| 2021 | 35.70B | -22.66B | -298M |
| 2022 | 28.10B | -26.38B | -2.42B |
| 2023 | 58.87B | -41.37B | -26.86B |
| 2024 | 45.43B | -40.28B | -3.76B |
RDY Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 5.77B | 14.85B | 14.82B | 1.96B | 2.22B | 2.54B | 3.77B | 4.92B | 5.39B | 8.45B |
Operating activities | ||||||||||
Net income | 55.68B | 60.48B | 23.56B | 19.14B | 19.49B | 18.79B | 9.80B | 12.03B | 20.01B | 22.17B |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 14.84B | 12.50B | 11.82B | 12.79B | 12.47B | 12.19B | 11.71B | 11.27B | 10.25B | 8.1B |
Stock-based compensation expense | 821M | 397M | 592M | 584M | 521M | 389M | 454M | 398M | 471M | 498M |
| Deferred income tax benefit | 821M | 397M | 592M | 584M | 521M | 389M | 454M | 398M | 471M | 498M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -8.05B | -5.75B | -17.01B | 2.08B | -12.44B | 1.79B | -2.09B | 3.03B | 833M | -10.90B |
Inventories | -18.44B | -2.65B | -5.32B | -9.88B | -1.48B | -8.49B | -3.23B | -6.32B | -2.52B | -5.44B |
Accounts payable | 0 | 5.75B | 17.01B | -2.08B | 12.44B | -1.79B | 0 | 0 | 0 | 0 |
Cash generated by operating activities | 45.43B | 58.87B | 28.10B | 35.70B | 29.84B | 28.70B | 18.02B | 21.51B | 41.24B | 25.03B |
Investing activities | ||||||||||
Purchases Of Investments | -145.48B | -136.17B | -88.97B | -75.41B | -111.91B | -78.57B | -68.42B | -49.65B | -68.24B | -53.46B |
Investments In Property Plant And Equipment | -16.40B | -18.86B | -19.04B | -12.56B | -6.11B | -7.49B | -11.04B | -40.98B | -14.87B | -15.32B |
Acquisitions Net | -12M | 0 | -326M | -15.51B | 1.26B | 536M | 1.75B | -103M | -7.93B | -276M |
Cash generated by investing activities | -40.28B | -41.37B | -26.38B | -22.66B | -4.92B | -7.72B | -14.88B | -18.47B | -20.42B | -22.90B |
Financing activities | ||||||||||
Common Stock Issued | 805M | 368M | 334M | 269M | 4M | 0 | 1M | 1M | 1M | 206M |
Payments for dividends | -6.64B | -4.97B | -4.14B | -4.14B | -3.91B | -4.00B | -3.99B | -3.39B | -4.10B | -3.06B |
Repurchases of common stock | 0 | 0 | 0 | -1.19B | -474M | -535M | 13M | -15.69B | 0 | 0 |
Repayments of term debt | -1.14B | -1.01B | 2.73B | -4.49B | -23.4B | -15.18B | -13M | -5.22B | -11.70B | -3.71B |
Cash used in financing activities | -3.76B | -26.86B | -2.42B | -298M | -25.15B | -21.32B | -4.44B | -3.69B | -17.00B | -4.11B |
Net Change In Cash | 1.32B | -9.07B | 32M | 12.85B | -266M | -314M | -1.23B | -1.14B | -473M | -3.05B |
Cash at end of period | 7.10B | 5.77B | 14.85B | 14.82B | 1.96B | 2.22B | 2.54B | 3.77B | 4.92B | 5.39B |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |